罗格列酮对糖耐量减低患者脂联素水平的影响  

The Effect of Rosiglitazone on Serum Adiponectin Levels of Patients with Impaired Glucose Tolerance

作　　者：洪侃[1] 郁志明[1] 宫玲玲[1] 薛一峰[1] 袁庆芳[1] 石维[1] 

机构地区：[1]无锡市第五人民医院内分泌科,江苏无锡214071

出　　处：《苏州大学学报（医学版）》2006年第4期634-636,共3页Suzhou University Journal of Medical Science

基　　金：无锡市卫生局指令性计划

摘　　要：目的了解糖耐量减低(IGT)患者脂联素水平及罗格列酮干预的效果。方法20名正常对照和28例确诊为IGT的个体进入研究。所有IGT患者均服用罗格列酮4 mg,每日1次,共用3个月。服药前及服用3个月、12个月后分别测定血清胆固醇(TC)、甘油三酯(TG)、脂联素,口服葡萄糖耐量试验(OGTT),与OGTT同步测定的胰岛素(Ins 0分、120分),并测颈动脉内膜中层厚度(IMT)。统计分析正常对照与罗格列酮治疗前后脂联素的水平差异及与血脂、胰岛素抵抗、治疗前后IMT的相关性。结果IGT患者血清脂联素水平(8.70±4.93 mg/L)显著低于正常对照组(13.46±3.26 mg/L)(P<0.05)。经罗格列酮治疗3个月后,患者血糖、胰岛素抵抗明显改善,血清脂联素水平从8.70±4.93 mg/L显著升高到13.50±8.30 mg/L(P<0.05)。体重指数、TG、胰岛素抵抗指数和IMT是影响脂联素水平的最为显著的因素。结论罗格列酮除了可改善IGT患者的血糖,减轻胰岛素抵抗外,还能升高脂联素,改善动脉硬化。Objective To investigate the serum levels of adiponectin in patients with impaired glucose tolerance and the effect of rosiglitazone. Methods The serum adiponectin levels and intimamedia thickness of common carotid arteries were determined in 28 cases of impaired glucose tolerance and 20 non-diabetes controls were measured by ELISA method. Among them, 28 cases of impaired glucosse tolerance were treated for 12 weeks with rosiglitazone. Results There was significant difference of the serum adiponectin levels between impaired glucose tolerance and the non-diabetic controls （8.58 ± 2.72 mg/L vs 13.46 ± 3.26 rag/L, P 〈 0.05）. The blood glucose and insulin sensitivity were improved after 3 months treatment of rosiglitazone, while the adiponectin levels of impaired glucose tolerance were increased （8.58 ± 2.72 mg/L vs 14.37 ± 5.86 mg/L, P 〈 0.05）. Conclusion Rosiglitazone increases serum adiponectin levels of patients with impaired glucose tolerance, as well as improves the blood glucose level and insulin sensitivity.

关 键 词：糖耐量减低 脂联素 罗格列酮 

分 类 号：R587.1[医药卫生—内分泌]